Cargando…
High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma
The high-strength formulation of extrafine beclometasone dipropionate/formoterol fumarate (BDP/Form) 200/6 µg has been developed to step up inhaled corticosteroid treatment, without increasing the dose of the bronchodilator, in patients who are not controlled with previous therapies. Two clinical st...
Autores principales: | Corradi, Massimo, Spinola, Monica, Petruzzelli, Stefano, Kuna, Piotr |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933614/ https://www.ncbi.nlm.nih.gov/pubmed/27340255 http://dx.doi.org/10.1177/1753465816654442 |
Ejemplares similares
-
Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma
por: Kuna, Piotr, et al.
Publicado: (2022) -
Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease
por: Singh, Dave, et al.
Publicado: (2016) -
Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide
por: Singh, Dave, et al.
Publicado: (2017) -
Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler(®) Device in Healthy Subjects, Asthmatic Patients, and COPD Patients
por: Virchow, Johann Christian, et al.
Publicado: (2018) -
High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids
por: Paggiaro, Pierluigi, et al.
Publicado: (2016)